AbbVie Inc.

ABBV
Pharmaceutical preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance SheetCash Flow
Period
Annual Quarterly
Order

10 more years with Pro

AbbVie Inc. back to 2013, every line as filed.

Create a free account
USD ($)
$ in Millions 		LTMDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013
Cash flows from operating activities
              
Net earnings
$ 6,316
$ 4,233
$ 4,286
$ 4,873
Adjustments to reconcile net earnings to net cash from operating activities:
              
Depreciation
777
762
764
752
Amortization of intangible assets
7,092
7,377
7,622
7,946
Deferred income taxes
(250)
(492)
(1,449)
(2,889)
Change in fair value of contingent consideration liabilities
6,087
6,495
3,771
5,128
Payments of contingent consideration liabilities
(3,241)
(2,865)
(1,995)
(870)
Stock-based compensation
976
955
911
747
Acquired IPR&D and milestones
5,016
5,016
2,757
778
Other charges related to collaborations
-
-
-
0
Gain on divestitures
-
-
0
0
Non-cash litigation reserve adjustments, net of cash payments
(97)
(933)
508
(443)
Devaluation loss related to Venezuela
-
-
-
-
Impairment of intangible assets
847
847
4,476
4,229
Impacts related to U.S. tax reform
-
-
-
-
Acquired in-process research and development
-
-
-
-
Other, net
(117)
(3)
(63)
(225)
Changes in operating assets and liabilities, net of acquisitions:
              
Accounts receivable
(1,276)
(1,490)
207
66
Accounts and other receivables
-
-
-
-
Inventories
(350)
(234)
(319)
(417)
Prepaid expenses and other assets
(908)
(827)
361
(188)
Accounts payable and other liabilities
740
951
177
3,840
Income tax assets and liabilities, net
(2,069)
(762)
(3,208)
(488)
Cash flows from operating activities
19,507
19,030
18,806
22,839
Cash flows from investing activities
              
Acquisition of businesses, net of cash acquired
0
(204)
(17,493)
0
Other acquisitions and investments, net of cash acquired
(5,053)
(5,237)
(3,024)
(1,223)
Acquisitions of property and equipment
(1,297)
(1,214)
(974)
(777)
Purchases of investment securities
-
(35)
(73)
(77)
Sales and maturities of investment securities
-
76
555
55
Other, net
(172)
(29)
189
13
Cash flows from investing activities
(6,498)
(6,643)
(20,820)
(2,009)
Cash flows from financing activities
              
Net change in commercial paper borrowings with original maturities of three months or less
(1,549)
499
-
-
Proceeds from Short-Term Debt
791
4,798
5,008
-
Repayments of Other Short-Term Debt
(4,798)
(2,798)
(5,008)
-
Net change in short-term borrowings
-
-
-
-
Proceeds from issuance of long-term debt
7,991
3,994
16,963
-
Repayments of long-term debt and finance lease obligations
(2,017)
(6,797)
(9,613)
(4,149)
Debt issuance costs
(23)
(23)
(99)
(38)
Dividends paid
(11,978)
(11,657)
(11,025)
(10,539)
Purchases of treasury stock
(1,505)
(980)
(1,708)
(1,972)
Proceeds from the exercise of stock options
-
172
214
180
Payments of contingent consideration liabilities
0
0
0
(752)
Net transactions with Abbott Laboratories, excluding noncash items
-
-
-
-
Other, net
63
68
57
48
Cash flows from financing activities
(12,891)
(12,724)
(5,211)
(17,222)
Effect of exchange rate changes on cash and equivalents
(16)
42
(65)
5
Net change in cash and equivalents
102
(295)
(7,290)
3,613
Net (decrease) increase in cash and equivalents
-
-
-
-
Other supplemental information
              
Interest paid, net of portion capitalized
3,002
3,002
2,811
2,469
Income taxes received
-
-
-
-
Income taxes paid
-
-
4,064
4,702
Supplemental schedule of non-cash investing and financing activities
              
Issuance of common shares associated with acquisitions of businesses
-
-
-
-